Add 2 More Reports For 20% off

Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Diabetic Macular Edema Market Outlook

The diabetic macular edema market size was valued at USD 6.7 billion in 2023, driven by the increasing incidence of diabetes cases within the 8 major markets. The market size is anticipated to grow at a CAGR of 5.1% during the forecast period of 2024-2032 to achieve a value of USD 10.4 billion by 2032.

Diabetic Macular Edema Market Overview

Diabetic retinopathy occurs in people with diabetes where the tiny blood vessels located at the back inner wall of the eye, known as the retina, get damaged or blocked by too much blood sugar. This can result in the formation of microaneurysms, which are tiny bulges in the blood vessels that leak fluid into the retina. The swollen fluid can cause vision problems or blindness in a part of the retina known as the macula, which is referred to as diabetic macular edema.

The market is driven by the rising prevalence of diabetes and diabetic macular edema. The prevalence rate of diabetic macular edema (DME) in type 2 diabetes patients is recorded to be higher than in type 1 diabetes patients. It is estimated that neovascular age-related macular degeneration (AMD) affects more than 200 million people worldwide. The increase in the number of research and development activities providing beneficial opportunities for treatment are driving the diabetic macular edema market growth. The rising approvals and launches of new drugs, along with rising investment in the development of advanced technologies is also expected to contribute to the market growth during the forecast period.

Technological Advancements to Develop Effective Solutions

The market growth is expected to be driven by several factors such as increased advancements in diagnostics technology and therapeutics for diabetic macular edema. For instance, in July 2023 researchers at the University of Waterloo’s School of Pharmacy developed a novel synthetic protein to treat macular degeneration and other incurable eye diseases that lead to blindness in millions of people. It is the first drug of its kind and is currently in human trials. Continuous efforts like  these, focused at developing a cure for untreatable conditions are likely to increase the diabetic macular edema market share in the forecast period.

FDA Approvals to Aid the Market Growth

The market growth is propelled by rising FDA approvals to potent and cost-effective solutions to the patients. For instance, in August 2023, the United States FDA approved Regeneron’s EYLEA HD (aflibercept) Injection 8 mg for treating diabetic macular edema and other eye conditions. The approval was based on the results of 48-week PULSAR and PHOTON trials, wherein the potential candidate helped in significant vision gains in patients. This FDA approval will contribute to the widespread distribution and consumption of the pharmaceutical resulting in increased diabetic macular edema market value in the forecast period.

Diabetic Macular Edema Market Segmentations

Market Breakup by Disease Type

  • Focal Diabetic Macular Edema (DME)
  • Diffuse Diabetic Macular Edema (DME)

Market Breakup by Treatment Type

  • Oral Iron Therapy
  • Parenteral Iron Therapy
  • Red Blood Cell Transfusion

Market Breakup by Diagnosis

  • Hospitals Fluorescein Angiography
  • Fundus Imaging
  • Optical Coherence Tomography (OCT)
  • Others

Market Breakup by Route of Administration

  • Intravitreal Injections
  • Intravitreal Implants

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Market Breakup by End User

  • Hospitals
  • Clinics
  • Home Healthcare
  • Others

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan
  • India

Diabetic Macular Edema Market Regional Analysis

Geographically, the United States is expected to lead throughout the forecast period, owing to the presence of a robust healthcare system and major market players. The continuous research activities in the region also contribute to the market growth. There has been significant emphasis on leveraging gene therapy to allow access to improved solutions. In November 2023, scientists deployed gene therapy ABBV-RGX-314 to allow controlled release of dexamethasone in patients with diabetic macular edema and retinal vein occlusion. Developed by collaborative efforts of RegenXBio and AbbVie, ABBV-RGX-314 is a monoclonal antibody fragment, administered through an injection. When tested in a cohort of 100 patients with DME, it reduced vision threatening events by 89% and prevented disease progression as well. Hence, it can be used as a potential treatment in the future.

Europe, with its robust healthcare infrastructure and significant portion of geriatric population has high diabetic macular edema market demand. Consequently, the existence of prominent academic and research institutions aids market size, with continuous developments and activities to develop effective solutions for the patients in the region.

Diabetic Macular Edema Market: Competitor Landscape

In May 2023, Oculis, a global pharmaceutical company prioritising eye care, revealed that their latest topical eye drop OCS-01, displayed positive results from stage 1 of phase 3 DIAMOND trial . The treatment provides an edge over current treatment alternatives of the disease, which mostly involve ocular implants or injections. It utilises Oculis' Optireach technology to deliver the effective medication to the retina. The rising prevalence for minimally invasive treatment alternatives has led to the development of relevant initiatives by industry leaders.

The key features of the diabetic macular edema market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

  • LEO Pharma
  • Amneal Pharmaceuticals
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Bausch Health Companies Inc.
  • Eli Lilly and Company
  • AbbVie Inc.
  • Abbott
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.

Please note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Disease Type
  • Treatment Type 
  • Diagnosis
  • Route of Administration
  • Distribution Channel
  • End User
  • Region
Breakup by Disease Type
  • Focal Diabetic Macular Edema (DME)
  • Diffuse Diabetic Macular Edema (DME)
Breakup by Treatment Type
  • Oral Iron Therapy
  • Parenteral Iron Therapy
  • Red Blood Cell Transfusion
Breakup by Diagnosis
  • Hospitals Fluorescein Angiography
  • Fundus Imaging
  • Optical Coherence Tomography (OCT)
  • Others
Breakup by Route of Administration
  • Intravitreal Injections
  • Intravitreal Implants
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
Breakup by End User
  • Hospitals
  • Clinics
  • Home Healthcare
  • Others
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
  • India
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • LEO Pharma 
  • Amneal Pharmaceuticals 
  • AstraZeneca 
  • Johnson & Johnson Private Limited 
  • Bausch Health Companies Inc. 
  • Eli Lilly and Company 
  • AbbVie Inc. 
  • Abbott 
  • F. Hoffmann-La Roche Ltd. 
  • Mylan N.V. 

Diabetic Macular Edema Market Report Snapshots

Diabetic Macular Edema Market Size

Diabetic Macular Edema Market Regional Analysis

Diabetic Macular Edema Treatment Companies

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The market attained a value of about USD 6.7 billion in 2023 driven by increasing incidence of diabetes across the 8 major markets.

The market is anticipated to grow at a CAGR of 5.1% during the forecast period of 2024-2032 and is likely to reach a market value of USD 10.4 billion by 2032.


The increasing research and development activities to discover a cure for condition, integration of technical advancements and prevalence for minimally invasive treatments are fuelling the market demand. 
 

The surge in FDA approvals to facilitate improved solutions to the patients is a major market trend. In August 2023, FDA approved Regeneron’s EYLEA HD (aflibercept) Injection 8 mg for treating diabetic macular edema and related eye conditions. The approval was based on the results of 48-week PULSAR and PHOTON trials, wherein the drug candidate helped in significant vision gains in patients.

Based on disease type, the market is divided into focal diabetic macular edema and diffuse diabetic macular edema.

Hospitals fluorescein angiography, fundus imaging, and optical coherence tomography (OCT) among others are common diagnostic methods.

The route of administration can include intravitreal injections and implants.

The major regions of the market include the United States, EU-4, the United Kingdom, Japan and India.

Various types of treatments include oral iron therapy, parenteral iron therapy, and red blood cell transfusion.

Major distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others.

End users in the market are hospitals, clinics, and home healthcare, among others.

Key players involved in the market are LEO Pharma, Amneal Pharmaceuticals, AstraZeneca, Johnson & Johnson Private Limited, Bausch Health Companies Inc., Eli Lilly and Company, AbbVie Inc., F. Hoffmann-La Roche Ltd., Mylan N.V., and Abbott.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,499

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,699

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,599

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,599

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124